vs
Side-by-side financial comparison of loanDepot, Inc. (LDI) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
loanDepot, Inc. is the larger business by last-quarter revenue ($310.3M vs $158.6M, roughly 2.0× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -7.2%, a 78.4% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 20.5%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-648.0M).
LoanDepot, sometimes stylized as loanDepot, is an Irvine, California-based nonbank holding company which sells mortgage and non-mortgage lending products.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
LDI vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $310.3M | $158.6M |
| Net Profit | $-22.5M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | -10.3% | 70.2% |
| Net Margin | -7.2% | 71.2% |
| Revenue YoY | 20.5% | 3661.1% |
| Net Profit YoY | 32.4% | 528.0% |
| EPS (diluted) | — | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $310.3M | — | ||
| Q3 25 | $323.3M | — | ||
| Q2 25 | $282.5M | — | ||
| Q1 25 | $273.6M | $158.6M | ||
| Q4 24 | $257.5M | $22.6M | ||
| Q3 24 | $314.6M | — | ||
| Q2 24 | $265.4M | — | ||
| Q1 24 | $222.8M | — |
| Q4 25 | $-22.5M | — | ||
| Q3 25 | $-4.9M | — | ||
| Q2 25 | $-13.4M | — | ||
| Q1 25 | $-21.9M | $112.9M | ||
| Q4 24 | $-33.2M | $-10.5M | ||
| Q3 24 | $1.4M | — | ||
| Q2 24 | $-32.2M | — | ||
| Q1 24 | $-34.3M | — |
| Q4 25 | -10.3% | — | ||
| Q3 25 | -3.2% | — | ||
| Q2 25 | -11.4% | — | ||
| Q1 25 | -16.8% | 70.2% | ||
| Q4 24 | -32.7% | -60.4% | ||
| Q3 24 | 1.1% | — | ||
| Q2 24 | -29.1% | — | ||
| Q1 24 | -38.2% | — |
| Q4 25 | -7.2% | — | ||
| Q3 25 | -1.5% | — | ||
| Q2 25 | -4.7% | — | ||
| Q1 25 | -8.0% | 71.2% | ||
| Q4 24 | -12.9% | -46.4% | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | -12.1% | — | ||
| Q1 24 | -15.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $1.90 | ||
| Q4 24 | — | $-0.15 | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $-0.18 | — | ||
| Q1 24 | $-0.19 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $337.2M | $274.8M |
| Total DebtLower is stronger | $2.1B | — |
| Stockholders' EquityBook value | $386.0M | $350.1M |
| Total Assets | $6.9B | $406.9M |
| Debt / EquityLower = less leverage | 5.44× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $337.2M | — | ||
| Q3 25 | $459.2M | — | ||
| Q2 25 | $408.6M | — | ||
| Q1 25 | $371.5M | $274.8M | ||
| Q4 24 | $421.6M | $128.0M | ||
| Q3 24 | $483.0M | — | ||
| Q2 24 | $533.2M | — | ||
| Q1 24 | $603.7M | — |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.3B | — |
| Q4 25 | $386.0M | — | ||
| Q3 25 | $433.3M | — | ||
| Q2 25 | $439.1M | — | ||
| Q1 25 | $469.3M | $350.1M | ||
| Q4 24 | $506.6M | $229.0M | ||
| Q3 24 | $592.0M | — | ||
| Q2 24 | $578.9M | — | ||
| Q1 24 | $637.3M | — |
| Q4 25 | $6.9B | — | ||
| Q3 25 | $6.2B | — | ||
| Q2 25 | $6.2B | — | ||
| Q1 25 | $6.4B | $406.9M | ||
| Q4 24 | $6.3B | $271.6M | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $5.9B | — | ||
| Q1 24 | $6.2B | — |
| Q4 25 | 5.44× | — | ||
| Q3 25 | 4.83× | — | ||
| Q2 25 | 4.70× | — | ||
| Q1 25 | 4.30× | — | ||
| Q4 24 | 4.00× | — | ||
| Q3 24 | 3.31× | — | ||
| Q2 24 | 3.41× | — | ||
| Q1 24 | 3.63× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-638.7M | $131.8M |
| Free Cash FlowOCF − Capex | $-648.0M | $131.7M |
| FCF MarginFCF / Revenue | -208.9% | 83.0% |
| Capex IntensityCapex / Revenue | 3.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $-734.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-638.7M | — | ||
| Q3 25 | $43.4M | — | ||
| Q2 25 | $67.6M | — | ||
| Q1 25 | $-179.9M | $131.8M | ||
| Q4 24 | $47.7M | $-23.2M | ||
| Q3 24 | $-349.2M | — | ||
| Q2 24 | $-278.3M | — | ||
| Q1 24 | $-278.5M | — |
| Q4 25 | $-648.0M | — | ||
| Q3 25 | $38.7M | — | ||
| Q2 25 | $61.4M | — | ||
| Q1 25 | $-186.7M | $131.7M | ||
| Q4 24 | $40.8M | $-23.2M | ||
| Q3 24 | $-356.4M | — | ||
| Q2 24 | $-285.7M | — | ||
| Q1 24 | $-283.3M | — |
| Q4 25 | -208.9% | — | ||
| Q3 25 | 12.0% | — | ||
| Q2 25 | 21.7% | — | ||
| Q1 25 | -68.2% | 83.0% | ||
| Q4 24 | 15.8% | -102.7% | ||
| Q3 24 | -113.3% | — | ||
| Q2 24 | -107.7% | — | ||
| Q1 24 | -127.2% | — |
| Q4 25 | 3.0% | — | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 2.2% | — | ||
| Q1 25 | 2.5% | 0.1% | ||
| Q4 24 | 2.7% | 0.2% | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 2.8% | — | ||
| Q1 24 | 2.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | -255.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
